Drilldown/Medicines
Use the filters below to narrow your results.
generic:
3-MMC (1) ·
4-FA (1) ·
5-APB (1) ·
5-MAPB (1) ·
6-APB (1) ·
6-APDB (1) ·
Butylone (1) ·
Cathinone (1) ·
Ephylone (1) ·
Ethcathinone (1) ·
Ethylone (1) ·
Hexedrone (1) ·
Lisdexamfetamine (dimesylate) (1) ·
MDA (1) ·
MDAI (1) ·
MDEA (1) ·
MDMA (1) ·
Mephedrone (1) ·
Methcathinone (1) ·
Methylone (1) ·
Mexedrone (1) ·
Modafinil (1) ·
N-Ethylhexedrone (1) ·
N-Ethylpentedrone (1) ·
Pentedrone (1) ·
PMA (1) ·
PMMA (1)
brand:
classes: (Click arrow to add another value)
mechanism:
Cathinone analogue; monoamine reuptake inhibitor (2) ·
MAO inhibitor; monoamine releasing agent (1) ·
MAO inhibitor; serotonin releasing agent (1) ·
Monoamine releasing agent (5) ·
Monoamine releasing agent; 5-HT2A agonist (1) ·
Monoamine releasing agent; active ingredient in khat (1) ·
Monoamine releasing agent; serotonergic at higher doses (1) ·
Norepinephrine and dopamine releasing agent (1) ·
Norepinephrine/dopamine releasing agent (1) ·
Norepinephrine/dopamine reuptake inhibitor (1) ·
Serotonin releasing agent (2) ·
Serotonin releasing agent; 5-HT2A agonist (3) ·
Serotonin releasing agent; monoamine reuptake inhibitor (1) ·
Serotonin/dopamine/norepinephrine releasing agent; 5-HT2A agonist (1) ·
Serotonin/norepinephrine/dopamine releasing agent (3) ·
'"`UNIQ--vote-00000013-QINU`"' Once converted, dextroamphetamine acts by displacing dopamine and norepinephrine from presynaptic vesicles via VMAT-2 and reversing DAT and NET transport, the shared mechanism of all amphetamine-class agents'"`UNIQ--ref-00000014-QINU`"'. (1) ·
'"`UNIQ--vote-00000049-QINU`"' (1)
starting dose:
None (25) ·
ADHD: 30 mg PO once daily in the morning; titrate by 10-20 mg weekly to clinical effect. Binge-eating disorder: 30 mg/day, titrate to 50-70 mg/day (1) ·
Narcolepsy/OSA: 200 mg PO once daily in the morning. Shift work disorder: 200 mg PO approximately 1 hour before the start of the work shift. Lower starting dose (100 mg) can be considered in elderly patients or those with hepatic impairment. (1)
preparations:
fda max:
routes:
onset:
None (25) ·
1-2 hours (slower than immediate-release amphetamine because activation requires enzymatic cleavage in red blood cells) (1) ·
Peak plasma concentrations 2-4 hours after oral dose. Wakefulness-promoting effect onset correlates with peak plasma; subjective alertness typically reported within 1-2 hours of dosing. (1)
duration:
None (25) ·
10-12 hours (smoother profile than immediate-release amphetamine salts) (1) ·
Effective wakefulness promotion through approximately 12-15 hours reflecting the half-life of the predominant R-enantiomer. For shift-work use, 200 mg taken 1 hour before shift provides coverage through most 8-12 hour shifts. (1)
halflife:
bioavailability:
pregnancy:
Showing below up to 32 results in range #1 to #32.